Asuragen’s microRNA-based test, miRInform Pancreas, has demonstrated improvements in the diagnosis of pancreatic ductal adenocarcinoma.
The data from the multicentre study involving 186 subjects showed that the miRNA-based molecular test will improve the diagnostic accuracy of fine-needle aspiration cytology on indeterminate and suspicious specimens.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
miRInform Pancreas, along with standard fine-needle aspiration cytology, allows pancreatic ductal adenocarcinoma to be diagnosed with 92.5% accuracy, as compared to 80.2% for fine-needle aspiration cytology alone.
Brigham and Women’s Hospital Dr Darwin Conwell said that the microRNA-based molecular test helps to identify false negative cytology.
The molecular test will be available in the company’s CLIA Laboratory from 1 December 2011.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
